Could Gene Therapy Be One Step Closer to the Clinic?
Drug manufacturer Spark Therapeutics announced positive results in a phase III trial for a gene therapy treatment for inherited retinal dystrophies, a progressive disorder that can cause blindness. Katherine High, president and chief scientific officer at Spark Therapeutics, and Richard Jude Samulski, director of the Gene Therapy Group at the University of North Carolina, discuss the treatment and the future of gene therapies.
Catherine A. High is the resident and chief scientific officer of Spark Therapeutics in Philadelphia, Pennsylvania.
Richard Jude Samulski is the director of the Gene Therapy Center at the University of North Carolina in Chapel Hill, North Carolina.